A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel.
Epistemonikos ID: 32036c72e9feb7cf7d9c7cb82c14c72d3d91f60b
First added on: May 04, 2024